cancer

ADCs are reshaping biopharma. Biointron explores how antibody-drug conjugates combine precision targeting with potent payloads to transform therapies.

Trastuzumab revolutionized breast cancer therapy as the first HER2-targeting antibody. Biointron reviews its approval and enduring impact on oncology.

Rituximab marked a milestone as the first cancer antibody. Biointron reviews its approval, clinical use, and role in shaping oncology therapeutics.

Antibody immunotherapy is transforming cancer care. Biointron explains how antibodies complement traditional treatments to improve patient outcomes.

Bispecific antibodies fight cancer via unique mechanisms. Biointron highlights how bsAbs target multiple pathways to expand therapeutic impact.

Antibody-drug conjugates (ADCs) have seen significant developments in regulatory review, with several notable announcements in the past few weeks. Innate Pharma received FDA clearance for its investigational new drug (IND) application for IPH4502, a novel topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4. Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues.

ADCs and checkpoint inhibitors create synergy in oncology. Biointron explains how combining these modalities improves precision and patient outcomes.

Bispecific antibodies are rapidly transforming the therapeutic landscape, especially in oncology and autoimmune diseases. Such recombinant molecules can bind to two different antigens at the same time, offering greater specificity in targeting disease pathways. Since their introduction, the area of bispecifics has held tremendous promise in oncological cancers like multiple myeloma and lymphomas.

T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is an immune receptor that plays a key role in suppressing T-cell activation and proliferation. As a newly identified checkpoint, it is highly expressed on various immune cells, including CD4+ and CD8+ T cells, NK cells.

News from the IASLC 2024 World Conference on Lung Cancer (WCLC24) has provided several updates on the clinical trial space for non-small cell lung cancer (NSCLC), with several antibody-based drugs at the forefront. NSCLC is the most common type of lung cancer, accounting for about 85% of all cases.

Bispecific antibodies transform in vivo research. Biointron highlights how BsAbs expand therapeutic potential by targeting multiple pathways with precision.

​A recent editorial by researchers at Yale University School of Medicine describes how we are entering the golden age for antibody-drug conjugates (ADCs) in gynecologic cancer, which includes difficult to treat tumors such as uterine carcinosarcomas and platinum-resistant ovarian cancer.

Antibody-mediated phagocytosis strengthens anti-cancer responses. Biointron explores how ADCP mechanisms support immunotherapy and enhance therapeutic outcomes.

Immune checkpoint inhibitors transform oncology. Biointron explains PD-1, CTLA-4, and related therapies that unlock immune responses to fight cancer effectively.

Immune checkpoint blockade antibody therapy is an approach in cancer treatment that uses the body's immune system to target and destroy cancer cells. Immune checkpoints are regulatory pathways in immune cells that cancer cells exploit to evade detection. Key immune checkpoints include PD-1, PD-L1, and CTLA-4. By blocking these pathways, antibodies like pembrolizumab, nivolumab, and ipilimumab allow T-cells to recognize and attack cancer cells more effectively.